Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections

Carbohydrate Polymers, Год журнала: 2024, Номер 348, С. 122930 - 122930

Опубликована: Окт. 30, 2024

Язык: Английский

---

Anticoagulants utilization in eight hospitals within the Luzhou region from 2019 to 2023

PLoS ONE, Год журнала: 2025, Номер 20(1), С. e0318463 - e0318463

Опубликована: Янв. 31, 2025

With the increasing utilization of anticoagulants, selection appropriate anticoagulants has emerged as a significant quandary. The objective this study was to evaluate recent trend in and expenditure within specific region, aiming provide valuable insights into optimal choice across other healthcare facilities. retrospectively analyzed. data on anticoagulant utilizations tertiary-care hospitals district were collected from January 2019 December 2023. expenditure, defined daily doses (DDDs), cost (DDC) calculated. trends examined using linear regression analysis. From 2023, DDDs rivaroxaban demonstrated annual increase most (p < 0.05). Only few exhibited gradual rise consumption low molecular weight heparin (LMWH) over same period sodium warfarin varied different hospitals. implementation centralized procurement policy, however, resulted decline LMWH 2021 2022 respectively. DDC value experienced substantial decrease past five years = 0.020), declining 55.20 Chinese Yuan (CNY) 4.28 CNY Conversely, there slight noted during time frame 0.042). Over (2019-2023), been an LMWH. However, their decreased. In addition, remained relatively stable. application prospects are promising.

Язык: Английский

---

Expanding the Role of Heparin Derivatives in Oncology: From Anticoagulation to Antitumor Activity

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 396 - 396

Опубликована: Март 12, 2025

Current research demonstrates the expanding therapeutic potential of heparin derivatives in oncology, extending beyond traditional anticoagulation mechanisms. This systematic analysis examines structural characteristics, molecular mechanisms, and applications heparin-based compounds malignancy treatment. The essential antithrombin binding pentasaccharide sequence has enabled development specialized variants, particularly fractionated heparins their non-anticoagulant counterparts. These agents exert antineoplastic effects via multiple pathways, through modulation heparanase enzymatic activity specific protein–glycosaminoglycan interactions. Evidence from pivotal clinical trials (FRAGMATIC, MAGNOLIA, GASTRANOX) confirms efficacy managing cancer-associated thrombosis while indicating enhancement chemotherapeutic outcomes. preparation methods utilize cleavage reactions selective chemical derivatization to generate structurally modified exhibiting unique characteristics biological activities. Analysis glycosaminoglycan analog dociparstat sodium reveals significant myeloid malignancies, mediated by interference with CXCL12/CXCR4 signaling cascades. Significant challenges remain manufacturing scale-up, analytical validation, long-term safety assessment. Future studies must address dose optimization, combination strategies, controlled determine full these oncology.

Язык: Английский

---

Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting

Artificial Organs, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 15, 2024

Abstract Background Appropriate anticoagulation is crucial for the success of left ventricular assist device patients. Currently, there no consensus on optimal management their subtherapeutic INR in ambulatory setting. Our goal to evaluate both short‐term adverse events and long‐term outcomes enoxaparin bridging at a major transplant center, following implementation safety criteria. Methods In total, 85 patients' medical records were reviewed between 7/2019 5/2022, with 51 patients meeting criteria bridged 34 non‐bridged. The primary endpoint was occurrence bleeding/thrombosis within 30 days bridging. secondary freedom from after initiation overall patient survivability until last follow‐up. Results Within days, bleeding/thrombotic noted. After bleeding rate 5.8% vs. 11.8% non‐bridged ( p = 0.02). Overall, 3‐year survival 78% 49% < 0.001). events, 80% 58% 55% 51% 0.11). At 1 year, 81% 0% those an event 0.0001). Conclusion When eligibility safe applied, use associated during improved LVAD Economically, using outpatient resulted substantial healthcare savings, fewer readmissions, quality life.

Язык: Английский

---

Endothelial cell dysfunction in cancer: a not-so-innocent bystander

Bleeding Thrombosis and Vascular Biology, Год журнала: 2024, Номер 3(s1)

Опубликована: Май 16, 2024

The body’s homeostasis depends on the vascular endothelium, which controls angiogenesis, tone, inflammation, cell trafficking, hemostasis, and movement of nutrients waste out body. Endothelial cells (ECs) are primary gatekeepers many these vessel wall functions, despite only having a single cell’s thickness. Normally quiescent ECs in context cancer activated by anti-cancer therapies, tumor microenvironment, factors secreted tumor. Crucially, this dysfunctional endothelium actively participates metastasis progression rather than just acting as passive bystander. Compared to healthy vasculature, vasculature heterogeneous have different gene expression profile. Tumor-associated ECs, particular, exhibit increased pro-angiogenic characteristics upregulated adhesion molecules proinflammatory cytokines, facilitating intra- extravasation spreading cells. Furthermore, downregulation important anticoagulant endothelial secretion prothrombotic can directly encourage cancer-associated thrombosis. Many therapies also less effective their delivery function when there is dysfunction endothelium. review highlights some most recent research showing how tumor-associated influence coagulation, contribute tumors. Undoubtedly, better understanding microenvironment subverts phenotypic alterations support survival spread will aid identification new therapeutic targets slow advancement cancer.

Язык: Английский

---

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

International Journal of Biological Macromolecules, Год журнала: 2024, Номер unknown, С. 135833 - 135833

Опубликована: Сен. 1, 2024

Язык: Английский

---

Inflammatory Biomarkers as Predictors of Symptomatic Venous Thromboembolism in Hospitalized Patients with AECOPD: A Multicenter Cohort Study

Journal of Atherosclerosis and Thrombosis, Год журнала: 2024, Номер unknown

Опубликована: Янв. 1, 2024

Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by enhanced inflammatory response. This study aimed to evaluate the predictive value biomarkers for VTE AECOPD.

Язык: Английский

---